Upstream Bio (UPB) Expected to Post Earnings on Wednesday

Upstream Bio (NASDAQ:UPB) will likely be releasing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect Upstream Bio to post earnings of ($0.78) per share and revenue of $0.4310 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 9:30 AM ET.

Upstream Bio (NASDAQ:UPB) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). Upstream Bio had a negative net margin of 4,718.96% and a negative return on equity of 43.82%. The business had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $1.03 million. On average, analysts expect Upstream Bio to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Upstream Bio Stock Up 1.7%

UPB opened at $6.42 on Tuesday. The company has a market cap of $349.38 million, a PE ratio of -2.21 and a beta of 1.23. Upstream Bio has a twelve month low of $5.85 and a twelve month high of $33.68. The company has a 50-day moving average price of $6.96 and a 200 day moving average price of $11.28.

Institutional Investors Weigh In On Upstream Bio

A number of institutional investors have recently modified their holdings of UPB. BNP Paribas Financial Markets raised its stake in shares of Upstream Bio by 229.8% in the second quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after acquiring an additional 2,158 shares in the last quarter. Legal & General Group Plc boosted its stake in shares of Upstream Bio by 83.0% in the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock valued at $35,000 after buying an additional 1,440 shares during the period. Empowered Funds LLC acquired a new position in shares of Upstream Bio during the fourth quarter worth about $45,000. Russell Investments Group Ltd. increased its stake in shares of Upstream Bio by 1,963.9% during the third quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock worth $57,000 after buying an additional 2,887 shares during the period. Finally, AQR Capital Management LLC acquired a new stake in Upstream Bio in the first quarter valued at approximately $115,000.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on UPB. HC Wainwright began coverage on shares of Upstream Bio in a research note on Wednesday, June 3rd. They set a “buy” rating and a $36.00 price objective for the company. Weiss Ratings downgraded Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. JPMorgan Chase & Co. cut Upstream Bio from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $35.00 to $8.00 in a report on Friday, June 12th. Finally, Mizuho reduced their price target on Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a report on Thursday, May 14th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $33.17.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.